PHARMA HORIZONS

Pharma Horizons: Artificial Intelligence

EPR‘s inaugural Pharma Horizons report explores the latest advances in artificial intelligence (AI) and machine learning (ML) for drug development, pharmaceutical manufacturing and quality control.

AI/ML is predicted to be the top technology investment for 60 percent of life sciences companies over the next two years, according to a recent survey1 from the Pistoia Alliance. Additionally the pharmaceutical AI market is projected to reach $11.8 billion by 2032, driven by its ability to enhance manufacturing, clinical trials, and research & development.

Register now to access this exclusive content as we delve into some of the challenges and opportunities for AI in pharma, with exclusive insight from:

  • Dr Feng Ren, Chief Scientific Officer and Head of R&D at Insilico Medicine 
  • Dr Andrew Hopkins, founder of Exscientia, a company that brought four AI-generated drugs into the clinic in 2023
  • Tero Laulajainen, Head of Global Clinical Science at UCB
  • Vincenzo Salvatore, Legal Expert from BonelliErede 
  • Dr Tim Sandle, Microbiology expert 
  • Phoebe Clough, experienced QP.  

Stay abreast of the latest developments in AI and ML with articles including:

  • Augmenting clinical trials with AI
  • Enhancing contamination control methods: how AI is shaping microbiology and QP oversight
  • Leveraging generative AI in quality control
  • Exchanging trial and error for transformative technology.

Interested? Register your details now to download for free today!